Recombinant Mouse CD40 Protein

• Cat.No.: CD40-630M
• Product Overview: Recombinant Mouse CD40 protein without tag was expressed in HEK293.

Specification

• Description: Predicted to enable antigen binding activity; protein domain specific binding activity; and ubiquitin protein ligase binding activity. Involved in B cell mediated immunity; CD40 signaling pathway; and cellular calcium ion homeostasis. Acts upstream of or within several processes, including defense response to other organism; positive regulation of B cell activation; and positive regulation of interleukin-12 production. Located in external side of plasma membrane and intracellular membrane-bounded organelle. Part of CD40 receptor complex. Is expressed in several structures, including alimentary system; brain; hemolymphoid system gland; liver and biliary system; and reproductive system. Human ortholog(s) of this gene implicated in several diseases, including Kawasaki disease; autoimmune disease (multiple); end stage renal disease; hyperimmunoglobulin syndrome (multiple); and non-Hodgkin lymphoma (multiple). Orthologous to human CD40 (CD40 molecule).
• Source: HEK293
• Species: Mouse
• Form: Lyophilized
• Molecular Mass: 20.8 kDa
• Protein length: 289
• AA Sequence: MVSLPRLCALWGCLLTAVHLGQCVT CSDKQYLHDGQCCDLCQPGSRLTSH CTALEKTQCHPCDSGEFSAQWNREI RCHQHRHCEPNQGLRVKKEGTAESD TVCTCKEGQHCTSKDCEACAQHTPC IPGFGVMEMATETTDTVCHPCPVGF FSNQSSLFEKCYPWTSCEDKNLEVL QKGTSQTNVICGLKSRMRALLVIPV VMGILITIFGVFLYIKKVVKKPKDN EILPPAARRQDPQEMEDYPGHNTAA PVQETLHGCQPVTQEDGKESRISVQ ERQVTDSIALRPLV
• Purity: > 98%
• Applications: WB; ELISA; FACS; FC
• Stability: This bioreagent is stable at 4 centigrade (short-term) and -70 centigrade(long-term). After reconstitution, sample may be stored at 4 centigrade for 2-7 days and below -18 centigrade for future use.
• Storage: At -20 centigrade.
• Concentration: 1 mg/mL
• Storage Buffer: PBS (pH 7.4-7.5). Sterile-filtered colorless solution.
• Reconstitution: Reconstitute in sterile distilled H2O to no less than 100 μg/mL; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.

Gene Information

• Gene Name: Cd40 CD40 antigen [ Mus musculus (house mouse) ]
• Official Symbol: CD40
• Synonyms: CD40; CD40 antigen; tumor necrosis factor receptor superfamily member 5; CD40L receptor; B-cell surface antigen CD40; T-cell differentiation antigen; tumor necrosis factor receptor superfamily, member 5; IGM; p50; Bp50; GP39; IMD3; TRAP; HIGM1; T-BAM; Tnfrsf5; AI326936
• Gene ID: 21939
• mRNA Refseq: NM_011611
• Protein Refseq: NP_035741
• UniProt ID: P27512

Reviews

10/28/2021

Its utilization in this technique has allowed for precise visualization and determination of protein structures with remarkable clarity and resolution.

08/11/2021

The reliable and high-quality results obtained using CD40 protein make it an excellent choice for researchers studying protein structures.

10/07/2018

CD40 protein has proved to be an invaluable tool in protein electron microscopy structure analysis.

Q&As

Can CD40-targeted therapies be used in the treatment of infectious diseases?

CD40 agonists have the potential to enhance immune responses against infectious agents, but their clinical use in this context is an area of ongoing research.

Are there any approved drugs targeting CD40 for clinical use?

As of my knowledge cutoff date in January 2022, there were no FDA-approved drugs specifically targeting CD40. However, clinical trials were ongoing for CD40-targeted therapies.

Can CD40-targeted therapies be used in combination with other cancer treatments?

Yes, CD40-targeted therapies are often investigated in combination with other treatments like checkpoint inhibitors or chemotherapy to enhance their effectiveness.

What are the potential side effects of CD40-targeted therapies in cancer treatment?

Side effects may include flu-like symptoms, cytokine release syndrome, and immune-related adverse events, which can be managed with supportive care and close monitoring.

Are there ongoing clinical trials exploring CD40-targeted therapies for atherosclerosis?

Research on CD40-targeted therapies for atherosclerosis is still in the experimental stages and not yet in advanced clinical trials.